Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.

Sax, Paul E.; Erlandson, Kristine M.; Lake, Jordan E; McComsey, Grace A.; Orkin, Chloe; Esser, Stefan; Brown, Todd T.; Rockstroh, Jürgen K; Wei, Xuelian; Carter, Christoph C.; Zhong, Lijie; Brainard, Diana M.; Melbourne, Kathleen; Das, Moupali; Stellbrink, Hans-Jürgen; Post, Frank A; Waters, Laura; Koethe, John R

doi:10.1093/cid/ciz999

Record: found
Abstract: found
Article: found

Is Open Access

Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.

Author(s): Paul Sax, Kristine Erlandson, Jordan Lake, Grace McComsey, Chloe Orkin, Stefan Esser, Todd Brown, Jürgen K Rockstroh, Xuelian Wei, Christoph Carter, Lijie Zhong, Diana Brainard, Kathleen Melbourne, Moupali Das, Hans-Jürgen Stellbrink, Frank Post, Laura Waters, John R Koethe

Publication date: 2020-09-12

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Publisher: Oxford University Press (OUP)

Keywords: weight gain, ART, obesity, HIV, antiretroviral therapy

Read this article at

ScienceOpenPublisher PMC

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Initiation of antiretroviral therapy (ART) often leads to weight gain. While some of this weight gain may be an appropriate return-to-health effect, excessive increases in weight may lead to obesity. We sought to explore factors associated with weight gain in several randomized comparative clinical trials of ART initiation.

Related collections

Most cited references 39

Record: found
Abstract: found
Article: not found

Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV

Willem Venter, Michelle Moorhouse, Simiso Sokhela … (2019)

Two drugs under consideration for inclusion in antiretroviral therapy (ART) regimens for human immunodeficiency virus (HIV) infection are dolutegravir (DTG) and tenofovir alafenamide fumarate (TAF). There are limited data on their use in low- and middle-income countries.

0 comments Cited 200 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Obesity and the environment: where do we go from here?

J O Hill (2003)

The obesity epidemic shows no signs of abating. There is an urgent need to push back against the environmental forces that are producing gradual weight gain in the population. Using data from national surveys, we estimate that affecting energy balance by 100 kilocalories per day (by a combination of reductions in energy intake and increases in physical activity) could prevent weight gain in most of the population. This can be achieved by small changes in behavior, such as 15 minutes per day of walking or eating a few less bites at each meal. Having a specific behavioral target for the prevention of weight gain may be key to arresting the obesity epidemic.

0 comments Cited 114 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.

Jamison Norwood, Megan Turner, Carmen Bofill … (2017)

With the introduction of integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy, persons living with HIV have a potent new treatment option. Recently, providers at our large treatment clinic noted weight gain in several patients who switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to dolutegravir/abacavir/lamivudine (DTG/ABC/3TC). In this study, we evaluated weight change in patients with sustained virologic suppression who switched from EFV/TDF/FTC to an INSTI-containing regimen.